Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Lonza today announced that its Board of Directors has approved the appointment of Daniel Palmacci as President of its Cell & Gene Division. The appointment will be effective from 1 November 2022. Daniel takes over the role from Jean-Christophe Hyvert, who continues to serve as President of Lonza’s Biologics Division.

Daniel joins Lonza Group with more than two decades of experience in the pharmaceutical industry, including senior positions at Novartis and Bayer Healthcare. He also brings a wealth of international experience, having previously held roles in Switzerland, Germany, Italy, India, Brazil, France and the US.

Most recently Daniel served as Senior Vice President, Global Head of Technical Operations and Executive Committee member at MorphoSys, a commercial-stage biopharmaceutical company. In this role, he transformed the Technical Operations function with a focus on improving its commercialization capabilities. He also oversaw the digitalization and AI strategy of MorphoSys, with a view to accelerating clinical development.

Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division. The appointment builds on the recent achievements and ongoing growth of both Divisions under Jean-Christophe’s leadership since January 2021. The expanded Executive Committee structure provides a dedicated President for each of Lonza’s four Divisions, thereby maximizing the growth potential of each area of the business.

Albert M. Baehny, Chairman, Lonza, commented: “We extend a warm welcome to Daniel as he joins the Lonza Group Executive Committee and takes on the leadership of Cell & Gene. Daniel is well placed to lead our Cell & Gene Division, as a seasoned leader in the pharmaceuticals industry with a proven track record working with novel breakthrough therapies.”

Pierre-Alain Ruffieux, CEO, Lonza, added: “Daniel’s expertise in leading cross-functional teams will take our diverse offerings within Cell & Gene into a new stage of growth and development. I extend my gratitude to Jean-Christophe for his dedicated leadership of both our Biologics and Cell & Gene Divisions since January 2021. With Jean-Christophe now solely dedicated to leading our Biologics offering, we are positioned to consolidate our leading market position and maintain our focus on long-term success across both Divisions.”

Daniel holds a Masters in Chemistry and Process Engineering from Technical University Berlin, Germany. He is relocating from Munich (DE) to Basel (CH), where Lonza is headquartered.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine